Alternative 5-Azacitidine 5-Day 100 mg/m<sup>2</sup> Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment.

EJHaem · 2025 · PMC12648631 · PMID 41311530

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significancep = 0.12not close (p > 0.1)

Although a similar trend was noticed for PLT TI, it did not reach statistical significance ( p = 0.12, Figure 2f ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Alternative 5-Azacitidine 5-Day 100 mg/m&lt;sup&gt;2&lt;/sup&gt; Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment.

The sentences

Alternative 5-Azacitidine 5-Day 100 mg/m<sup>2</sup> Dosage Shows Non-Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment.